Direction

Mr. Karras assumed the role of Group CEO at Halo Pharma in May 2026, following its spin out from the Noramco Group as a standalone drug product CDMO. He previously served as Group Chief Executive Officer of the Noramco Group an API business which was sold to Siegfried in May 2026. Prior to his leadership at Noramco, he was a Director at SK Capital Partners, where he provided operational, sales, and general management guidance to various healthcare portfolio companies. Mr. Karras previously served as President of IBA Molecular North America (also an SK Capital Partners portfolio company) that was sold to Illinois Health and Sciences in 2015. Before IBA, Mr. Karras was President and CEO of AAIPharma Services Company where he led the company’s transition from bankruptcy to a successful exit in 2009. Prior to AAI, Lee held various positions at Baxter Healthcare and Cook Medical (Cook and Baxter Pharmaceutical Solutions), where he served as General Manager and helped build the pharmaceutical services start up into a sizable sterile injectable pharma services business.

Lee est titulaire d'une licence en chimie de l'Université de l'Indiana à Bloomington et d'une maîtrise en sciences de l'environnement de l'École des affaires publiques et environnementales de l'Université de l'Indiana à Bloomington.